Printer Friendly

Akorn unveils two additional Promethazine syrup formulations in the US for respiratory symptoms.

M2 PHARMA-September 18, 2015-Akorn unveils two additional Promethazine syrup formulations in the US for respiratory symptoms

(C)2015 M2 COMMUNICATIONS

Pharmaceutical company Akorn (NasdaqGS:AKRX) on Thursday reported the market availability of Promethazine Hydrochloride and Phenylephrine Hydrochloride Syrup (Promethazine/Phenylephrine) and Promethazine Hydrochloride, Phenylephrine Hydrochloride and Codeine Phosphate Syrup CV. (Promethazine/Phenylephrine/Codeine) in the US.

The company added that both the abbreviated new drug applications (ANDAs) were approved by the US Food and Drug Administration (FDA) in December 2014.

According to the company, Promethazine/Phenylephrine Syrup is indicated for the temporary relief of upper respiratory symptoms, including nasal congestion, associated with allergy or the common cold.

Marketed under Akorn's Hi-Tech Pharmacal label, fruit-flavored Promethazine/Phenylephrine Syrup is available in a 473 ml bottle. According to IMS Health, branded and generic sales of Promethazine/Phenylephrine Syrup were approximately USD9m for the 12 months ended 31 July 2015.

In addition, the company's Promethazine/Phenylephrine/Codeine Syrup is indicated for the temporary relief of coughs and upper respiratory symptoms, including nasal congestion, associated with allergy and the common cold.

Also marketed under Akorn's Hi-Tech Pharmacal label, fruit-flavored Promethazine/Phenylephrine/Codeine Syrup is available in 118 ml and 473 ml bottles. According to IMS Health, branded and generic sales of Promethazine/Phenylephrine/Codeine Syrup were approximately USD16m for the 12 months ended 31 July 2015.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2015 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2015 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Sep 18, 2015
Words:233
Previous Article:Can-Fite BioPharma awarded the US FDA fast frack designation for CF102 for the treatment of liver cancer, hepatocellular carcinoma.
Next Article:Allergan and Gedeon Richter announces the US FDA's approval for VRAYLAR capsules for the acute treatment of bipolar I disorder and schizophrenia.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters